Last reviewed · How we verify
reducing anticholinergic burden
reducing anticholinergic burden is a Small molecule drug developed by Ankara City Hospital Bilkent. It is currently FDA-approved for Reduction of anticholinergic medication burden in elderly or polypharmacy patients, Prevention of cognitive decline and delirium in older adults, Reduction of fall risk and urinary retention in patients on multiple anticholinergic agents. Also known as: not reducing anticholinergic burden, routine care.
Reducing anticholinergic burden involves discontinuing or deprescribing medications with anticholinergic properties to minimize cumulative anticholinergic effects.
Reducing anticholinergic burden has been studied in various conditions, including postoperative recovery, complications, and physical function, with interventions such as deprescribing anticholinergic and sedative medications. A randomized controlled study (NCT06349057) investigated anticholinergic burden as a modifiable risk factor in cardiac surgery, suggesting its potential impact on patient outcomes.
At a glance
| Generic name | reducing anticholinergic burden |
|---|---|
| Also known as | not reducing anticholinergic burden, routine care |
| Sponsor | Ankara City Hospital Bilkent |
| Modality | Small molecule |
| Therapeutic area | Geriatric Medicine / Deprescribing |
| Phase | FDA-approved |
Mechanism of action
Anticholinergic medications block acetylcholine receptors and can cause cognitive impairment, urinary retention, constipation, and increased fall risk, particularly in elderly patients. Reducing anticholinergic burden is a deprescribing strategy that systematically identifies and removes or replaces anticholinergic drugs with safer alternatives. This approach improves patient safety and reduces adverse outcomes associated with high anticholinergic exposure.
Approved indications
- Reduction of anticholinergic medication burden in elderly or polypharmacy patients
- Prevention of cognitive decline and delirium in older adults
- Reduction of fall risk and urinary retention in patients on multiple anticholinergic agents
Common side effects
Key clinical trials
- The Effect of the Anticholinergic Burden Following Elective Coronary Artery Surgery (PHASE4)
- ItaliaN Study With Tailored Multidomain Interventions to Prevent Functional and Cognitive Decline in Community-dwelling Older Adults (NA)
- Impact in Older Adults of Reducing Anticholinergic and Sedative Rx Burden on Physical Function Measured by Wearables (PHASE4)
- Anticholinergic Burden in Schizophrenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- reducing anticholinergic burden CI brief — competitive landscape report
- reducing anticholinergic burden updates RSS · CI watch RSS
- Ankara City Hospital Bilkent portfolio CI
Frequently asked questions about reducing anticholinergic burden
What is reducing anticholinergic burden?
How does reducing anticholinergic burden work?
What is reducing anticholinergic burden used for?
Who makes reducing anticholinergic burden?
Is reducing anticholinergic burden also known as anything else?
What development phase is reducing anticholinergic burden in?
Related
- Manufacturer: Ankara City Hospital Bilkent — full pipeline
- Therapeutic area: All drugs in Geriatric Medicine / Deprescribing
- Indication: Drugs for Reduction of anticholinergic medication burden in elderly or polypharmacy patients
- Indication: Drugs for Prevention of cognitive decline and delirium in older adults
- Indication: Drugs for Reduction of fall risk and urinary retention in patients on multiple anticholinergic agents
- Also known as: not reducing anticholinergic burden, routine care
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing